Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study)

. (2020). Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). CLINICAL CARDIOLOGY, 43(10), 1055-1063. SID. https://sid.ir/paper/979870/en

. Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study). CLINICAL CARDIOLOGY[Internet]. 2020;43(10):1055-1063. Available from: https://sid.ir/paper/979870/en

, “Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: The three C study),” CLINICAL CARDIOLOGY, vol. 43, no. 10, pp. 1055–1063, 2020, [Online]. Available: https://sid.ir/paper/979870/en